Marinus

Committed to improving the lives of patients affected by seizure disorders.

[Marinus @MarinusPharma]

Genetic testing can help patients receive appropriate clinical management for their specific conditions. Learn more about the benefits of a confirmed genetic diagnosis for refractory seizures.

[Marinus @MarinusPharma]

Stop by our booth at the @AmEpilepsySoc Conference to learn more about CDKL5 deficiency disorder and discuss treatment options for those impacted by this rare genetic epilepsy disorder.

[Marinus @MarinusPharma]

Our team had an incredible experience at the annual Epilepsy Awareness Day at Disneyland! We engaged with epilepsy physicians and patients to raise awareness about the vital needs and services available to the community. Check out the photos!

[Marinus @MarinusPharma]

Today, we reported our Q3 2024 earnings and business updates. Learn more in our press release: https://t.co/HjwSTMz0TV

[Marinus @MarinusPharma]

Today, we shared topline results from our Phase 3 TrustTSC trial. Read more in our press release: https://t.co/zp4mVPl1Nm

[Marinus @MarinusPharma]

At just under a year old, Judith was diagnosed with CDKL5 deficiency disorder, a rare, X-linked DEE characterized by early-onset, refractory seizures & severe global developmental impairment. Watch the full episode: https://t.co/cJwnyLn55J

[Marinus @MarinusPharma]

Today, we presented data from our pivotal Phase 3 RAISE trial in refractory status epilepticus at the @neurocritical Annual Meeting. Learn more in our press release: https://t.co/aSdjGsTbC8

[Marinus @MarinusPharma]

Today, we announced that the USPTO issued Marinus a new method of treatment patent for ZTALMY titration regimens, further strengthening our IP estate. Learn more: https://t.co/TQNHnfqnjn

[Marinus @MarinusPharma]

Join us at the 2024 @neurocritical Annual Meeting where we will be presenting additional data from the pivotal Phase 3 RAISE trial and data from a retrospective claims-based analysis. Read more in our press release: https://t.co/ci6Hd0wkKk

[Marinus @MarinusPharma]

Thank you to everyone who joined our Investor and Analyst Day, where we shared updates from our fully enrolled Phase 3 trial in TSC and new follow-up data from patients who completed our Phase 2 TSC trial and entered the long-term extension. Learn more https://t.co/hzloaJwnoM

[Marinus @MarinusPharma]

Today, during our Investor & Analyst Day, we’re discussing the significant progress we’re making in our mission to improve the lives of individuals affected by rare genetic epilepsies. Learn more in today’s press release: https://t.co/ND2Fk2mltV

[Marinus @MarinusPharma]

Our Investor & Analyst Day starts at 9:00 am ET tomorrow! We’re looking forward to sharing updates about our clinical progress and vision for the future. Members of the investment community can register for the event and view our webcast here: https://t.co/ThoITKQDCE

[Marinus @MarinusPharma]

Tomorrow, our Chairman and CEO, Scott Braunstein, and our CFO and COO, Steven Pfanstiel, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference. Register here for the webcast: https://t.co/9o7nQrGqrt

[Marinus @MarinusPharma]

Save the date for our Investor & Analyst Day on September 20! Tune in for the latest updates on our Phase 3 program in tuberous sclerosis complex and vision for the future. Learn more about the event and how to register: https://t.co/J7sf8Z0q57

[Marinus @MarinusPharma]

Now airing! Step into the lives of Judith and her family as they navigate life with #CDKL5 deficiency disorder in a new episode of Medical Stories docuseries airing via the PBS local stations. Stay tuned for more! #CDDAwareness https://t.co/kM2lLcG6VG

[Marinus @MarinusPharma]

John Flatt, MD, Medical Director, recently sat down with @XTalks to discuss how Marinus is addressing the unmet medical needs of patients and families affected by rare genetic epilepsy disorders. Read the full article here: https://t.co/3RxFIgppE5

[Marinus @MarinusPharma]

Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the TSC1 gene or TSC2 gene. Learn more about this condition.

[Marinus @MarinusPharma]

Marinus will be hosting an Investor and Analyst Event on September 20 in New York and via webcast. Learn more about the event and how to register: https://t.co/YepQRE59df

[Marinus @MarinusPharma]

We were honored to host Carly at our TSC Town Hall, where she shared insights into her life as a caregiver for her son Logan, who is living with TSC. Thank you, Carly, for sharing your story and reminding us why we do what we do.

[Marinus @MarinusPharma]

Hosted by the @EFEPA, Marinus was a proud sponsor of Camp Achieve, a summer camp tailored to the unique needs of kids living with epilepsy. Yesterday, our Marinus team volunteered at the Camp Olympics, a day of team-building & friendly competition with the campers.